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Abstract
Diabetes mellitus is recognized as a leading cause of new cases of blindness. The prevalence of diabetic eye disease is
expected to continue to increase worldwide as a result of the dramatic increase in the number of people with diabetes. At
present, there is no medical treatment to delay or prevent the onset and progression of cataract or retinopathy, the most
common causes of vision loss in diabetics. The plant Emblica officinalis (gooseberry) has been used for thousands of years as
a traditional Indian Ayurvedic preparation for the treatment of diabetes in humans. Extracts from this plant have been
shown to be efficacious against the progression of cataract in a diabetic rat model. Aldose reductase (ALR2) is implicated in
the development of secondary complications of diabetes including cataract and, therefore, has been a major drug target for
the development of therapies to treat diabetic disease. Herein, we present the bioassay-guided isolation and structure
elucidation of 1-O-galloyl-b-D-glucose (b-glucogallin), a major component from the fruit of the gooseberry that displays
selective as well as relatively potent inhibition (IC50=17mM) of AKR1B1 in vitro. Molecular modeling demonstrates that this
inhibitor is able to favorably bind in the active site. Further, we show that b-glucogallin effectively inhibits sorbitol
accumulation by 73% at 30 mM under hyperglycemic conditions in an ex-vivo organ culture model of lenses excised from
transgenic mice overexpressing human ALR2 in the lens. This study supports the continued development of natural
products such as b-glucogallin as therapeutic leads in the development of novel therapies to treat diabetic complications
such as cataract.
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Introduction
Diabetes mellitus is recognized as a leading cause of new cases
of blindness throughout the world, and the rapid increase in the
incidence of diabetes in recent years suggests that diabetic eye
disease could become an even larger public health problem in the
near future [1]. Diabetic patients face a 25-fold increased risk of
blindness as a result of diabetic retinopathy and/or cataract in
comparison with the general population. While strict long term
control of blood glucose can reduce the likelihood of developing
retinal lesions leading to retinopathy [2], present methods for
achieving strict metabolic control are not suitable for most diabetic
patients because of excessive cost and complexity. Therefore,
patient education, lifestyle modifications, and new technologies
such as blood glucose monitors and insulin pumps collectively will
still fall short of effectively preventing diabetic eye disease for the
general population. Numerous clinical trials and experimental
animal studies have shown that early intervention is required to
achieve maximal reduction in the onset and severity of diabetic
retinopathy and cataracts [2,3]. Therefore, medical therapies
developed to delay the onset and progression of diabetic eye
disease must be sufficiently safe and well tolerated to allow lifelong
treatment.
Many theories have been advanced to explain the pathogenesis
of diabetic eye disease. These include excess formation of
advanced glycation end-products (AGEs), activation of the
glucosamine pathway, activation of PKC isoforms, and activation
of the polyol pathway [4]. The first step of the polyol pathway is
catalyzed by aldose reductase, which converts glucose to sorbitol
with concomitant oxidation of NADPH to NADP
+ (Note: ALR2
will be used in generic reference to aldose reductase. In cases
referring to aldose reductase of a defined species origin, we will use
the standard nomenclature adopted for the aldo-keto reductase
superfamily, such as AKR1B1 for human aldose reductase. ALR1
will be used in generic reference to aldehyde reductases).
Accelerated flux of glucose through the polyol pathway has been
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groups have reported that ALR2 becomes activated in diabetic
tissues [5–7]. We recently showed that elevated ALR2 activity
measured in erythrocytes was associated with risk for developing
retinopathy among patients with type 2 diabetes [8]. Enhance-
ment of ALR2 activity by creating transgenic animals causes
exacerbation of diabetic eye disease, including cataract [9] and
retinopathy [10,11]. In contrast, inactivation of the ALR2 gene by
targeted gene deletion protects against diabetes-induced cataract
and histopathological markers of retinopathy such as pericyte loss,
blood-retinal barrier breakdown, increased VEGF, and markers of
retinal nitrosative stress [12].
Given the close association between ALR2-mediated sorbitol
accumulation and diabetic eye disease, considerable effort has
been focused on developing ALR2 inhibitors to prevent diabetic
retinopathy. Although several structurally diverse inhibitors have
been studied clinically, none have been shown to prevent the onset
or worsening of diabetic retinopathy in humans. In contrast,
impressive results have been reported with several different ALR2
inhibitors against markers of diabetic retinopathy in animal
models. ALR2 inhibitors essentially prevent cataract [11], retinal
pericyte loss and the formation of acellular capillaries in diabetic
animal models [13,14]. These results appear to validate ALR2 as
an attractive target against diabetic eye disease and suggest that
development of more effective inhibitors optimized for human
therapy is needed.
Emblica officinalis, commonly known as Amla or the Indian
gooseberry, is extensively used in the practice of Ayurveda, Indian
traditional medicine, as a treatment for diabetes related complica-
tions [15]. Previous work has shown that crude aqueous extracts
from Amla fruit delayed the onset and progression of cataracts and
normalized diabetes-induced markers of lipid peroxidation and
protein carbonyls [16,17]. Moreover, these studies demonstrated
that the active component(s) of the aqueous extract penetrate the
lens and substantially delay the progression of cataracts through
ALR2 inhibition. In this study we present the isolation and
structure elucidation of the naturally occurring ALR2 inhibitor
from E. officinalis fruit to be 1-O-galloyl-b-D-glucose (b-glucogal-
lin). This well-known compound was first synthesized in 1918 by
Emil Fisher and has since been shown to be a key bioprecursor
found in numerous plants for larger, more complex tannins such as
the gallotannins and ellagitannins [18–22]. We demonstrate that
inhibition of substrate reduction is mM potent under saturating
substrate conditions for both glucose and glyceraldehyde, and find
that inhibition of substrate oxidation is noncompetitive for xylitol.
Additionally, we show that b-glucogallin inhibition of ALR2 is
specific over other aldo-keto reductases (AKRs) and active in an ex
vivo transgenic lens organ culture, preventing the accumulation of
sorbitol under hyperglycemic conditions.
Results
Isolation and Structure Elucidation of b-glucogallin
The aqueous extract of E. officinalis fruit has been shown to be
rich in active constituents such as tannins and other antioxidants
[16,23,24]. Thus, to facilitate identifying the active constituents
against human AKR1B1, the lyophilized aqueous extract was
further extracted with a 9:1 (acetone:water) solution and subjected
to SephadexH LH-20 flash chromatography. Forty-five of the
150 column chromatography fractions showed significant activity
against AKR1B1 in vitro. Material from the active fractions was
further purified using bioassay-guided fractionation via C18
reversed phase HPLC, which revealed the highest inhibitory
activity to be localized in one major fraction (Figure 1A). The
1H
NMR spectrum of this fraction is shown in Figure 1B, (acetone-d6
and D2O): d (ppm) 7.16 (2H, s), 5.65 (1H, d, J=7.8), 3.85 (1H, dd,
J=12.4, 1.1), 3.70 (1H, dd, J=12.4, 5.8), 3.41–3.48 (4H, m). The
13C NMR spectrum is shown in Figure S1, (DMSO-d6): d (ppm)
165.0, 146.0, 139.3, 119.2, 109.4, 95.0, 78.3, 77.1, 73.1, 70.0,
61.0. In conjunction with NMR data, this fraction was subjected to
LC-MS accurate mass analysis ([M+Na]
+ experimental: 355.0624,
calculated: 355.0606), which is consistent with the structure of b-
glucogallin, agreeing with other structural reports for this
compound in the literature (Figures 1, S1 and S2) [25,26].
Additionally, the b-glucogallin active fraction showed an m/z peak
at 687.089 (Figure 1C). Subsequent MS/MS analysis on ion m/
z 687.089 confirmed this ion to be a b-glucogallin aggregate
consisting of [2M aggregate + Na]
+. Aggregation is a common
phenomenon observed with saccharides during LC-MS analysis
[27]. We observed no other stray peaks in any of the analytical
spectra, confirming that the only compound present in the purified
active fraction was b-glucogallin.
Inhibition of Human Aldo-keto Reductases by b-
glucogallin
The inhibitory activity of purified b-glucogallin was determined
for AKR1B1, as well as human aldose reductase-like protein 1
(AKR1B10) and human aldehyde reductase (AKR1A1) using the
shared substrate glyceraldehyde to assess specificity amongst the
structurally similar family of AKRs (Figure 2) [28,29]. By
nonlinear regression, the IC50 value of b-glucogallin for AKR1B1
was determined to be 5863 mM (SEM). In contrast, negligible
inhibition was observed when assays were conducted using
AKR1B10 and AKR1A1. Using concentrations of glucose
representing both enzyme-saturating (1 M) and physiological
hyperglycemia (50 mM) conditions, the IC50 value was de-
termined to be 1761 and 1361 mM (SEM), respectively
(Figure 2). Detailed analysis of possible inhibition mechanisms
using glucose as the variable substrate was not possible due to high
and inconsistent rates of auto-oxidation in control reactions.
Alternatively, assays were carried out in the ‘‘reverse’’ direction,
using xylitol as the variable substrate with concomitant generation
of NADPH. Under these conditions, Michaelis-Menten behavior
was observed (Figure 3A) and inhibition appeared noncompetitive
in the Lineweaver-Burk plot (Figure 3B) as the slopes of the linear
fits are increased for the solutions with b-glucogallin present and
the y-intercept increases with increasing concentrations. Further,
by using nonlinear fits to the Michaelis-Menten model, no
significant (P$0.4) changes in the apparent Km of AKR1B1 for
xylitol were observed (Figure 3C) while the apparent Vmax
decreased significantly (P#0.05) with increasing concentrations
of b-glucogallin (Figure 3D), also in agreement with the model of
noncompetitive inhibition. Therefore, using the noncompetitive
inhibition model we found the inhibition constant (Ki) for the
oxidation of xylitol to be 170620 mM (SEM).
Overall, these data confirm our initial studies, which showed the
presence of an AKR1B1 inhibitor in the crude extracts from E.
officinalis [16]. In addition, our results indicate a high degree of
selectivity of b-glucogallin for AKR1B1 over the most abundant
other members of the human AKR family.
Computational Modeling of b-glucogallin with AKR1B1
The active site of AKR1B1 consists of two major pockets, the
so-called ‘‘anionic’’ pocket and the ‘‘specificity’’ pocket [30]. The
active site of AKR1B1 can accommodate a multitude of substrates
due to the flexibility of the ‘‘specificity pocket’’ residues [31].
Interestingly, deposited XRAY crystallography structures of
bound AKR inhibitors demonstrate that competitive, uncompet-
b -Glucogallin a Novel AKR1B1 Inhibitor from Amla
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e31399Figure 1. The elucidation of b-glucogallin as an active component and inhibitor of AKR1B1 from E. officinalis. (A) HPLC trace of pooled
SephadexH LH-20 fractions displaying activity against AKR1B1. The arrow indicates the fraction where activity against AKR1B1 appears to be localized.
(B) The
1H NMR spectrum of the abundant active fraction from HPLC purification. The
13C spectrum and accurate mass data are shown in Figure S1
and S2 respectively. All of these data identify the active component as b-glucogallin. C) LC/MS/MS data indicate a peak at 687 m/z as a [2M aggregate
+ Na]. Therefore, the only compound present in this active fraction is b-glucogallin.
doi:10.1371/journal.pone.0031399.g001
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[32–34]. To investigate how b-glucogallin may bind AKR1B1, we
carried out computational molecular docking studies using
Discovery Studio software and Ligand Scout. Using Discovery
Studio, a search of the AKR1B1 crystal structure surface was
conducted to identify available binding sites that would accom-
modate b-glucogallin using flexible and rigid docking. The
AKR1B1 active site was identified as the most likely binding site
due to the available area, high-scoring complexes, DOCK score,
binding energy, and the visualized protein ligand binding
conformation. Further, b-glucogallin bound the active site of
AKR1B1 obtaining a more favorable predicted binding energy
than sorbinil (–44 kcal/mol and –32 kcal/mol, respectively),
a known active site inhibitor of AKR1B1 (Figure 4) [30,35].
Sorbinil only binds to the anionic pocket and has been shown to
inhibit ALR1 and ALR2 equally. However, other inhibitors that
bind to both the ‘‘anionic’’ and ‘‘specificity’’ pockets show
specificity for ALR2 [31,33]. b-glucogallin occupies both the
‘‘anionic’’ and ‘‘specificity’’ pockets resulting in more active site
interactions (Figure 4C–D). Notably, the glucose moiety can form
key hydrogen bonds with active site residues in the anionic pocket,
including: Tyr48, Trp111, His110, Cys298, and the bound natural
cofactor NADP+ (Figure 4D). Additionally, the phenolic moiety of
b-glucogallin extends into the ‘‘specificity’’ pocket, potentially
forming hydrogen bonds with Ser302 and obtaining favorable
hydrophobic interactions with Leu300. These data suggest that b-
glucogallin can bind AKR1B1 as effectively as sorbinil, potentially
with greater affinity and specificity.
Lens Organ Culture Study with b-glucogallin
To confirm our in vitro data, we utilized a transgenic mouse
model, which overexpresses AKR1B1 specifically in the lens.
Lenses were dissected from both transgenic and non-transgenic
mice and cultured ex-vivo under high glucose conditions resulting in
sorbitol accumulation in transgenic lenses over 72 hours (Figure 5).
Transgenic lenses treated with 30 mM b-glucogallin under the
same conditions significantly (*P#0.05) inhibited sorbitol accu-
mulation by 73% (Figure 5). Similarly, lenses treated with the
positive control sorbinil (10 mM) inhibited sorbitol accumulation
by 97% (*P#0.05). No sorbitol accumulation was observed in the
non-transgenic mouse control lenses. These data not only indicate
that b-glucogallin can penetrate lens tissues ex-vivo, but can
successfully inhibit AKR1B1 under hyperglycemic conditions,
preventing the accumulation of sorbitol and subsequent osmotic
stress.
Discussion
Due to its involvement in the development of diabetic
complications, AKR1B1 is an attractive drug target in the clinical
management of secondary complications of diabetes including
cataract and retinopathy. As a result, AKR1B1 has been
extensively investigated using structure based drug design to
develop potent inhibitors [35]. Thus far, all of these man-made
inhibitors have failed to realize clinically useful therapies due to
toxicity and/or poor tissue penetration [36,37]. The Amla fruit
has been used in Ayurvedic medicinal preparations for thousands
of years as a safe and effective long-term treatment of diabetic
complications and other diseases of the eye [15]. We hypothesized
that this plant would provide inhibitors of AKR1B1 that could
lead to the identification of lead compounds that could be
exploited for novel drug development. In support of our hypothesis
we previously demonstrated that the crude aqueous extract
produced from fruits of E. officinalis suppressed the onset and
development of cataract in a rat model [16,17]. Furthermore, we
demonstrated that this extract could inhibit AKR1B1 enzyme
activity, suggesting that the efficacious effects against cataract
formation stem from inhibition of AKR1B1, preventing sorbitol
accumulation and subsequent osmotic stress.
In this study we successfully isolated an abundant fraction from
E. officinalis using bioassay-guided isolation. This major fraction
proved to be active against AKR1B1, which was not observed with
other fractions. Therefore, the inhibitory activity appears to be
localized as shown in Figure 1A. Structural analysis of the active
fraction revealed the active component to be b-glucogallin
(Figures 1, S1, and S2). Interestingly, b-glucogallin is a well-
known plant metabolite and major biosynthetic precursor for the
production of larger more complex hydrolysable tannoids [18–22].
Nevertheless, b-glucogallin has not been previously reported to
have significant biological activity against human disease. Indeed,
we show b-glucogallin is a relatively potent and selective inhibitor
of AKR1B1. Using the substrate glyceraldehyde, b-glucogallin
inhibited AKR1B1 with an IC50 value of 5863 mM (SEM)
(Figure 2). Structurally, AKR1B1 is similar to several AKRs in
human tissues, including the aldose reductase-like protein 1
(AKR1B10) and glucuronate reductase (AKR1A1; also known as
aldehyde reductase). Still, only negligible and non-dose-responsive
inhibition of AKR1B10 and AKR1A1 activity was observed even
with excessive concentrations of b-glucogallin ($ 100 mM).
Importantly, among these human AKRs, AKR1B1 is unique in
its ability to catalyze the NADPH-dependent conversion of glucose
to sorbitol [38]. While the galloyl moiety, which occupies the
‘‘specificity’’ pocket may confer specificity for ALR2 over ALR1
[31]; we theorize that the glucose moiety of b-glucogallin may be
the factor that confers specificity for AKR1B1 observed among the
Figure 2. Inhibition of AKR substrate reduction by b-glucogal-
lin. The IC50 was determined to be 5863 mM (SEM) under saturating
conditions of the shared substrate glyceraldehyde. b-glucogallin
showed no activity against AKR1B10 and AKR1A1 at all concentrations
tested under saturating conditions of glyceraldehyde as indicated. The
IC50 was determined to be 1761 mM under saturating conditions of the
substrate glucose, and did not decrease significantly when the
concentration of glucose was reduced 20-fold, IC50=1361 mM). For
all assays, inhibited enzyme activity was normalized to activity under
the same conditions in the absence of inhibitor, assays were repeated in
triplicate and error bars represent standard deviation from the mean.
Where possible, GraphPad Prism software was used to fit normalized
data to the enzyme inhibition model using nonlinear regression
(method of least squares).
doi:10.1371/journal.pone.0031399.g002
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result in toxicity and other adverse side effects.
To shed light on the pharmacological relevance of AKR1B1
inhibition by b-glucogallin, assays were conducted using condi-
tions that mimic either saturating or physiological (non-saturating)
concentrations of glucose. Since the observed potency of b-
glucogallin did not appreciably shift across a 20-fold range in
substrate concentration, i.e.1 7 62 mM in 1 M glucose vs.
1363 mM in 50 mM glucose (95% CI), the pattern of inhibition
for the reduction of glucose observed was not competitive
(Figure 2). Accordingly, b-glucogallin is similar to other ALR2
active site inhibitors, which show uncompetitive to noncompetitive
inhibition patterns when measured in the direction of aldehyde
reduction [32]. Inhibitor binding to ALR2 can give rise to
complex kinetic parameters depending on the range of enzyme
states recognized by the inhibitor and their associated binding
affinities, e.g., E, E-NADPH, or E-NADP
+ and the conformational
isomers associated with each of these [23]. Future studies will be
needed to establish these binding parameters.
Our computational molecular docking studies indicate that b-
glucogallin binds favorably to the active site of AKR1B1 (Figure 4).
The sugar moiety occupies the anionic site and appears to mimic
natural substrates of AKR1B1 by forming hydrogen bonds with
key residues that are necessary for catalytic function, as well as the
bound cofactor NADPH. The phenolic moiety extends into the
specificity pocket to form hydrophobic interactions as well as
hydrogen bonds with residues Leu300 and Ser302, respectively.
Therefore, we propose that b-glucogallin would inhibit free
glucose binding at the active site of AKR1B1, preventing sorbitol
production under hyperglycemic conditions such as in patients
suffering from diabetic eye disease. This is substantiated by our
observation that 30 mM b-glucogallin repressed sorbitol accumu-
lation by 73% in AKR1B1 transgenic mouse lenses incubated
under high glucose (27.5 mM) conditions that mimic hyperglyce-
mia in humans (Figure 5).
In conclusion, natural products such as b-glucogallin are
attractive as therapeutic leads in the treatment of diabetic
complications, since their low toxicity allows them to be used as
long-term prophylactics. In this context, we have been investigat-
ing the promise of dietary sources of aldose reductase inhibitors to
prevent diabetic cataract in animals. Thus far, we have successfully
identified and purified the most active AKR1B1 inhibitor from E.
officinalis as b-glucogallin, and have demonstrated its inhibitory
efficacy in vitro and in lens tissues in an ex-vivo model. Finally, this
study supports the continued development of b-glucogallin as
a therapeutic treatment against diabetic cataracts.
Figure 3. Inhibition of AKR1B1 substrate oxidation by b-glucogallin. A) Data were nonlinearly fit to the Michaelis-Menten model in the
absence and presence of 0, 10, 20, and 40 mM b-glucogallin. B) Lineweaver-Burk plot of the same data, depicting increasing slope and y-intercept
characteristic of noncompetitive inhibition. C) No significant changes were observed in the apparent Km values. D) A decreasing trend was observed
in the apparent Vmax values, and the differences were found to be statistically significant as follows: *indicates P=0.01, and ***indicates P=0.0002. All
assays were repeated in triplicate and error bars represent standard deviation from the mean. GraphPad Prism software was used to fit data to the
Michaelis-Menten model using nonlinear regression (method of least squares) and to determine significance by column analysis of triplicates using
the unpaired, two-tailed student’s t-test.
doi:10.1371/journal.pone.0031399.g003
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e31399Figure 4. Computational modeling studies with b-glucogallin and AKR1B1. Modeling comparison between sorbinil (A) and b-glucogallin (B)
showing ligands bound to AKR1B1. The solvent accessible surface depicts the active site anionic and specificity binding pockets, with expansion
images to emphasize the detail of each pocket. The calculated binding energies for sorbinil and b-glucogallin are –32 kcal/mol and –44 kcal/mol,
respectively. The active site interactions are summarized for sorbinil (C) and b-glucogallin (D) and were identified using Discovery Studio software
v2.5.5 (Accelrys) and Ligand Scout v2.3. Based on the calculated binding energies and number of active site interactions b-glucogallin appears to bind
AKR1B1 as effectively as the known active inhibitor sorbinil.
doi:10.1371/journal.pone.0031399.g004
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General Methods
Semi-preparative and analytical HPLC were performed using
an Agilent 1100 HPLC quaternary pump fitted with the
appropriate column as described below. HPLC solvents were
filtered through a 0.45 mm filter and degassed before use. HPLC-
grade solvents, all other chemical solvents, and biological reagents
described were purchased from Fisher Scientific (Pittsburgh, PA).
Sorbinil was a kind gift from Pfizer (New York, NY). NMR data
were collected using a Bruker Avance III 400 (
1H 400 MHz,
13C
100 MHz). LC-MS analyses were conducted using a Micromass
Q-TOF-2 Micromass spectrometer equipped with lock spray and
an Agilent 1100 HPLC capillary pump fitted with a C18 Mass
Spec column from Vydac (1X150mm). The MS was run in
positive mode with a capillary voltage of 2.5 kV and a cone
voltage of 30 V. Accurate mass measurements were performed
using leucine enkephalin as a lock mass and data were processed
using MassLynx 4.1. Spectroscopic kinetic analyses were per-
formed using a Cary Bio 100 UV/Vis spectrophotometer (Agilent)
in quartz cuvettes in conjunction Cary WinUV software.
Computational molecular docking was performed using Discovery
Studio software v2.5.5 (Accelrys) and Ligand Scout v2.3
(MacResearch).
Animal Protocol
The authors confirm that use of mice in these studies adheres to
policies in the Guide for the Care and Use of Laboratory Animals,
the United States Public Health Service Policy on the Humane
Care and Use of Laboratory Animals, and the U.S. Animal
Welfare Act. Approval for the use of mice was granted by the
University of Colorado-AMC Capitol Institutional Animal Care
and use Committee (IACUC Protocol Number: B-85109(04)1C).
Purification of AKR1B1 Inhibitors from E. officinalis
Fresh fruits of E. officinalis were collected from the local market
in Hyderabad (India) and the pericarp of the fruit was lyophilized.
An aqueous extract was prepared from the powdered material as
previously described and lyophilized [16]. The lyophilized powder
(10 g) was further extracted with 200 mL of a 9:1 (acetone: water)
solution and filtered. The aqueous acetone filtrate was loaded onto
the column (54 cm64 cm) packed with 100 g of SephadexH LH-
20 (Sigma-Aldrich; St. Louis, MO) previously saturated with
absolute ethanol (500 mL) over 24 hr. The crude aqueous acetone
extract was eluted sequentially with 600 mL absolute ethanol,
500 mL absolute ethanol and methanol (1:1), and 1,200 mL of
methanol, using a flow rate of 1.2 mL/min. The resulting eluent
was collected into 15 mL fractions, which were evaporated under
a stream of nitrogen and stored as a dry residue at 4uC. Fractions
determined to be active against AKR1B1 were purified by HPLC
using a Phenomenex Luna C18 reversed phase semi-prep column
(5 mm, 100 A ˚,1 0 6250 mm) fitted with a guard column. 180 mg
per injection was loaded onto the column and elution was
performed with a flow rate of 1.5 mL/min using a linear gradient
of 5–30% acetonitrile: water and a run time of 35 min, monitored
by absorbance at 280 nm. Fractions corresponding to absorbance
peaks were pooled and evaporated to dryness under a stream of
nitrogen.
Structure Elucidation
The active pure fraction was subjected to
1H and
13C NMR as
well as LC-MS for structural determination. The
1H NMR
(400 MHz) spectrum was obtained in acetone-d6 using a drop of
D2O to aid in dissolution. The
13C NMR (100 MHz) spectrum
was obtained in DMSO-d6. LC-MS analysis was conducted using
an initial isocratic mobile phase of 5% acetonitrile: water held for
2 minutes, followed by a linear gradient to 60% acetonitrile: water
over 8 minutes. The flow rate was maintained at 50 mL/min.
Following structural elucidation, solutions of pure b-glucogallin in
water were prepared for in-vitro and ex-vivo analysis.
Purification of Recombinant Human Aldo Keto
Reductases
Recombinant human aldose reductase (AKR1B1) was over-
expressed in E. coli and purified from bacterial cultures as
previously described [16,39]. By a similar method, quantities of
AKR1B10 (human aldose reductase-like protein 1) and AKR1A1
(human aldehyde reductase) were purified from E. coli expression
cultures. For all recombinant AKR enzymes used in this study, the
enzymes were purified to an apparently homogeneous state as
judged by the appearance of a single protein band following SDS-
PAGE of the purified material.
Inhibition of AKR1B1 and Other Members of the AKR
Family
Crude plant fractions were dissolved in DMSO at 20 mg/ml
and final concentration of DMSO was kept below 1% in enzyme
assay mixtures. Purified b-glucogallin was dissolved in water and
stored at –20uC until use. The activity of AKR1B1, AKR1B10
and AKR1A1 with glyceraldehyde and the activity of AKR1B1
with glucose was determined by the method of Hayman and
Kinoshita [40]. Briefly, the Km for glyceraldehyde was determined
by combining purified enzyme with a solution containing
saturating (175 mM) NADPH and varying concentrations of
glyceraldehyde in KAB buffer (50 mM Hepes (pH 7.5), 150 mM
NaCl, 1 mM DTT, 10 mM MgCl2). Solutions were kept on ice
before mixing, then incubated at 37uC and initial velocities were
Figure 5. b-glucogallin prevents sorbitol accumulation in
transgenic (TG) human AKR1B1 expressing lenses ex-vivo.
Lenses extracted from TG-animals were cultured under hyperglycemic
conditions in the presence or absence b-glucogallin (30 mM) or sorbinil
(10 mM) over 72 hours. b-glucogallin showed potent activity preventing
sorbitol accumulation by 73% as compared to untreated lenses.
Comparably, the positive control sorbinil inhibited sorbitol accumula-
tion by 97%. The amount of sorbitol in the non-transgenic controls was
below the limit of detection. GraphPad Prism software was used to
compare sorbitol accumulation in treated lenses to untreated controls
by column analysis of duplicates using the unpaired, one-tailed
student’s t-test. The * symbol denotes a statistically significant
difference (P,0.05) from untreated TG lenses.
doi:10.1371/journal.pone.0031399.g005
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corresponding to NADPH oxidation (stoichiometrically, one mole
of NADPH is oxidized to convert one mole of substrate). For
reactions with glucose, a final concentration of 375 mM NADPH
was used to provide saturating conditions for the larger
concentration of enzyme required to afford measurable reaction
rates.
IC50 assays were conducted similarly using a saturating
concentration of substrate, defined to be at least ten times greater
than the observed Km for that enzyme-substrate pair, as well as
physiological hyperglycemic conditions (50 mM glucose). For each
concentration of b-glucogallin used, enzyme activity was normal-
ized to that of activity using the same conditions in the absence of
inhibitor. The activity of AKR1B1 in the direction of substrate
oxidation was determined with xylitol [41]. Briefly, assays were
conducted as above using a final concentration of 2.5 mM NADP
+
and varying concentrations of xylitol in 50 mM phosphate buffer,
pH 7.0. In this case, enzyme activity was monitored on the same
principle, using the absorbance increase at 340 nm corresponding
to NADP
+ reduction.
Enzyme-free solutions were used to determine the mean and
standard deviation of the background signal for oxidation of
NADPH and reduction of NADP
+ and means were subtracted
from observed signals as appropriate. All kinetic experiments were
repeated in triplicate and GraphPad Prism software was used to fit
normalized data to the enzyme inhibition model for IC50 values,
the Michaelis-Menten model for Km and Vmax values, and the
noncompetitive inhibition model for the Ki value using nonlinear
regression (method of least squares). Double-reciprocal (Line-
weaver-Burk) data was linearly fit by the method of least squares in
order to compare slope and intercept values, however, these plots
were not utilized quantitatively to determine Michaelis-Menten
constants.
Ex-vivo Lens Organ Culture Studies
Transgenic mice designed for lens-specific expression of
AKR1B1 were produced by standard methods on a C57BL6
strain background. The current study was carried out using the
strain designated PAR40, which expresses AKR1B1 at approxi-
mately 30 milliunits/mg protein when cleared lens homogenates
were assayed under standard conditions [42]; in contrast,
AKR1B1 activity in lens homogenates from nontransgenic control
was practically undetectable. Lenses for organ culture studies,
which were harvested from 8–12 week old transgenic and
nontransgenic control mice, were morphologically normal. Mice
were euthanized under CO2, eyes were removed and lenses
dissected into Dulbecco’s Modified Eagle’s Medium (DMEM,
D5030, Sigma) supplemented with insulin/transferring/selenium
(Sigma), penicillin-streptomycin and fungizone (Gibco) and were
incubated in the presence of 95% O2,5 %C O 2 at 37uC. Lenses
that remained clear after 24 h incubation were then switched to
either DMEM containing 5.5 mM glucose (basal glucose) or
DMEM containing 27.5 mM glucose (high glucose) in the
presence or absence of b-glucogallin. Presence of lens opacities
was monitored daily. At the end of the experiment, sorbitol
content in the lenses was determined. Sorbitol content in cultured
lenses was estimated by an enzymatic method [43]. The total
soluble protein content was estimated by BCA method using BSA
as the standard.
Computational Modeling of b-glucogallin with AKR1B1
To investigate how b-glucogallin is able to bind AKR1B1, we
carried out computational-based molecular docking studies. The
CHARMM force field was applied to the 0.93 A ˚ AKR1B1 (PDB:
1PWM) crystal structure [44], water molecules were removed, and
residues were corrected for physiological pH. The binding site was
defined as whole residues within an 8 A ˚ radius subset encompass-
ing the active site. LigandFit [45] was used for the molecular
docking of b-glucogallin and sorbinil into the defined binding site
of AKR1B1. Grid resolution was set to 0.5 A ˚ and electrostatic
energy was included in the calculation of the ligand internal
energy. In order to avoid identical conformations, a root mean
square deviation threshold of 1.5 A ˚ and a score threshold of
20 kcal/mol were used. Fifty structural outputs were specified and
the identification of a docked conformation was followed by
a minimization using the conjugate gradient method to a conver-
gence of 0.001 kcal/mol to optimize ligand-protein interactions.
Active site interactions were determined utilizing the Structure
Monitor in Discovery Studio in conjunction with the Create
Pharmacophore protocol in LigandScout. The top-ranked con-
formations for each docked complex were selected on the basis of
the following criteria: the calculated binding energy and the
potential interactions between the protein and ligand.
Supporting Information
Figure S1 The
13C NMR spectrum of b-glucogallin
(DMSO-d6): d (ppm) 165.0, 146.0, 139.3, 119.2, 109.4,
95.0, 78.3, 77.1, 73.1, 70.0, 61.0.
(TIFF)
Figure S2 The LCMS accurate mass analysis of b-
glucogallin.
(TIF)
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